NTI

8.00%

6.9¢ neurotech international limited

Ann: Trading Halt, page-67

First 67 Last

ttppxx

180 Posts.

113

18/04/24

12:36

Post #: 73405993

Originally posted by ttppxx: ↑
QUESTION:“What was the keycatalyst for Neuron? FDA approval?”

RESPONSE

A) The chart I shared (extracted from NextInvestors) is an exact share price tracker for Neuren Pharmaceuticals, from 2021 toJanuary 2024 (not just 2021). The comments that Next have inserted, show the'catalysts' that preceded (or ‘led’) to the share price re-rates.

B) I have redone this as a table (attached) andextracted additional information from Neuren (just theannouncements). As can be seen, whenmatching events to share price re-rates, the Top 3 SP catalysts were:
1) Trial results (Retts) - (Announced 6th of Dec 2021). This caused the biggestjump to date!
2) FDA approval - (Announced 14th of March 2023). This caused the nextbiggest jump to date.
3) Trial results (Phelan-McDermid) - (Announced 18 Dec 2023). This is not markedon the Next Investors chart - they limited their comments (on the chart) to Rett Syndrome!

DATE
EVENT (CATALYST)
SHARE PRICE MOVES
(5 days)
1
07 Dec 2021
ANN: Positive topline results from Phase 3 trial in Rett syndrome
$1.70 to $4.00 (135%)
2
14 Mar 2023
ANN: FDA approves Daybue - the first treatment for Rett syndrome
$7.60 to $12.80 (68%)
3
18 Dec 2023
ANN: P2 trial shows significant improvements in Phelan-McDermid
$16.00 to $24.00 (50%)
The share price movements within those 2 to 5days post results were much higher than what happened in the interveningperiods: 6% per month rise from Rett P3 results to FDA announcement, and 2.7%per month rice post the FDA announcement up to the P2 Phelan-McDermid trialresults readout.

Indeed, NT1 is still behind. This is shownclearly on the Next Investors chart.
Expand
The response above is to a comment from @Tony barber.

The chart below (from Next Investors) seems well placed as part of a response to the question about catalysts that propelled Neuren to the very high SP that it is now at.

NTI is behind for sure, but still on a path that may have differences, but is not completely dissimilar to how Neuren travelled.

NTI Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held

Upvote

0 Great analysis

Top Stories

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

HLX

Helix investor makes partial takeover bid, proposing board changes

There are more pages in this discussion • 20 more messages in this thread...

First 67 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 6.9¢		Change -0.006(8.00%)		Mkt cap ! $70.21M

Open	High	Low	Value	Volume
7.5¢	7.7¢	6.9¢	$94.54K	1.345M

Buyers (Bids)

No.	Vol.	Price($)
3	94342	6.9¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	114626	1

View Market Depth

No.	Vol.	Price($)
3	94342	0.069
3	557184	0.068
2	154790	0.067
3	290000	0.066
5	418000	0.065

Price($)	Vol.	No.
0.070	114626	1
0.073	303587	2
0.074	40000	1
0.075	98582	1
0.076	90000	1

Last trade - 15.39pm 30/08/2024 (20 minute delay)

NTI (ASX) Chart

Ann: Trading Halt, page-67

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Lendlease sells off US east coast construction operations in latest global divestment push

The Calmer Co’s Anthony Noble reflects on record breaking FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Helix investor makes partial takeover bid, proposing board changes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	DATE	EVENT (CATALYST)	SHARE PRICE MOVES (5 days)
1	07 Dec 2021	ANN: Positive topline results from Phase 3 trial in Rett syndrome	$1.70 to $4.00 (135%)
2	14 Mar 2023	ANN: FDA approves Daybue - the first treatment for Rett syndrome	$7.60 to $12.80 (68%)
3	18 Dec 2023	ANN: P2 trial shows significant improvements in Phelan-McDermid	$16.00 to $24.00 (50%)

Ann: Trading Halt, page-67

Top Stories

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Lendlease sells off US east coast construction operations in latest global divestment push

The Calmer Co’s Anthony Noble reflects on record breaking FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Helix investor makes partial takeover bid, proposing board changes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News